EyePoint Pharmaceuticals announces first patient dosed in the global Phase 3 clinical trial of DURAVYU for the treatment of wet age-related macular degeneration.
EyePoint Pharmaceuticals has initiated the global Phase 3 LUGANO clinical trial for DURAVYU, an investigational therapy targeting wet age-related macular degeneration. The company aims for accelerated patient enrollment and aligns with FDA pathways for potential regulatory success.
Company Information
Company
EyePoint Pharmaceuticals, Inc.
Location
480 PLEASANT STREET
Watertown, Massachusetts, United States
About
EyePoint Pharmaceuticals, Inc. is committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases.
Fundz sees it the moment EyePoint Pharmaceuticals, Inc. ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
WatertownBiotechnologyHealthcareHealth CareTherapeuticsPharmaceutical